Health and Healthcare
Is Intra-Cellular's Schizophrenia Treatment in Trouble?
Published:
Last Updated:
Intra-Cellular Therapies Inc. (NASDAQ: ITCI) saw its shares dip on Wednesday after the firm announced that the U.S. Food and Drug Administration (FDA) has canceled the Psychopharmacologic Drugs Advisory Committee meeting scheduled for July 31 to discuss the New Drug Application (NDA) for lumateperone for the treatment of schizophrenia.
The firm recently provided additional information to the FDA in response to information requests relating to non-clinical studies. The FDA canceled the Advisory Committee meeting to allow sufficient time to review this news and any forthcoming information as they continue the NDA review.
Ultimately, this information may result in an extension of the September 27, Prescription Drug User Fee Act (PDUFA) target action date for the lumateperone NDA.
As a result, Intra-Cellular has a meeting scheduled with the FDA shortly, and it will provide an update following the meeting.
Note that lumateperone is a molecule that provides selective and simultaneous modulation of serotonin, dopamine and glutamate, three neurotransmitter pathways implicated in severe mental illness.
Shares of Intra-Cellular traded down about 3.5% on Wednesday, at $7.90 in a 52-week range of $7.41 to $23.62. The consensus price target is $29.71.
24/7 Wall St.Credit Card Companies Are Doing Something Nuts
Credit card companies are at war. The biggest issuers are handing out free rewards and benefits to win the best customers.
It’s possible to find cards paying unlimited 1.5%, 2%, and even more today. That’s free money for qualified borrowers, and the type of thing that would be crazy to pass up. Those rewards can add up to thousands of dollars every year in free money, and include other benefits as well.
We’ve assembled some of the best credit cards for users today. Don’t miss these offers because they won’t be this good forever.
Flywheel Publishing has partnered with CardRatings for our coverage of credit card products. Flywheel Publishing and CardRatings may receive a commission from card issuers.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
